Kesimpta FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Kesimpta (ofatumumab) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Development Timeline for Kesimpta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.